npj Precision Oncology (Jul 2024)
Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohort
- Nicolas Jacquin,
- Ronan Flippot,
- Julien Masliah-Planchon,
- Guillaume Grisay,
- Riwan Brillet,
- Célia Dupain,
- Maud Kamal,
- Isabelle Guillou,
- Nadège Gruel,
- Nicolas Servant,
- Pierre Gestraud,
- Jennifer Wong,
- Vincent Cockenpot,
- Andreia Goncalves,
- Janick Selves,
- Hélène Blons,
- Etienne Rouleau,
- Olivier Delattre,
- Claire Gervais,
- Christophe Le Tourneau,
- Ivan Bièche,
- Yves Allory,
- Laurence Albigès,
- Sarah Watson
Affiliations
- Nicolas Jacquin
- INSERM U830, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Center
- Ronan Flippot
- Department of Cancer Medicine, Institut Gustave Roussy, Université Paris-Saclay
- Julien Masliah-Planchon
- Somatic Genetic Unit, Department of Genetics, Institut Curie Hospital
- Guillaume Grisay
- Department of Cancer Medicine, Institut Gustave Roussy, Université Paris-Saclay
- Riwan Brillet
- Clinical Bioinformatic Unit, Department of Diagnostic and Theragnostic Medicine, Institut Curie Hospital
- Célia Dupain
- Department of Drug Development and Innovation (D3i), Institut Curie
- Maud Kamal
- Department of Drug Development and Innovation (D3i), Institut Curie
- Isabelle Guillou
- Department of Drug Development and Innovation (D3i), Institut Curie
- Nadège Gruel
- INSERM U830, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Center
- Nicolas Servant
- INSERM U900, CBIO-Centre for Computational Biology, Institut Curie Research Center, Mines ParisTech
- Pierre Gestraud
- INSERM U900, CBIO-Centre for Computational Biology, Institut Curie Research Center, Mines ParisTech
- Jennifer Wong
- Somatic Genetic Unit, Department of Genetics, Institut Curie Hospital
- Vincent Cockenpot
- Department of Pathology, Institut Curie Hospital
- Andreia Goncalves
- Department of Pathology, Institut Curie Hospital
- Janick Selves
- Department of Pathology, University Hospital of Toulouse (IUCT)
- Hélène Blons
- Department of Biochemistry, Pharmacogenetics and Molecular Oncology, Georges Pompidou European Hospital, APHP
- Etienne Rouleau
- PRISM Center for personalized medicine, Gustave Roussy Cancer Center
- Olivier Delattre
- INSERM U830, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Center
- Claire Gervais
- Department of Medical Oncology, Georges Pompidou European Hospital, APHP
- Christophe Le Tourneau
- Department of Drug Development and Innovation (D3i), Institut Curie
- Ivan Bièche
- Department of Genetics, Institut Curie Hospital, INSERM U1016, Université Paris Cité
- Yves Allory
- Department of Pathology, Institut Curie Hospital
- Laurence Albigès
- Department of Cancer Medicine, Institut Gustave Roussy, Université Paris-Saclay
- Sarah Watson
- INSERM U830, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Center
- DOI
- https://doi.org/10.1038/s41698-024-00648-0
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 6
Abstract
Abstract Metastatic carcinoma of presumed renal origin (rCUP) has recently emerged as a new entity within the heterogeneous entity of Cancers of Unknown Primary (CUP) but their biological features and optimal therapeutic management remain unknown. We report the molecular characteristics and clinical outcome of a series of 25 rCUP prospectively identified within the French National Multidisciplinary Tumor Board for CUP. This cohort strongly suggests that rCUP share similarities with common RCC subtypes and benefit from renal-tailored systemic treatment. This study highlights the importance of integrating clinical and molecular data for optimal diagnosis and management of CUP.
